Gilead Sciences (FRA:GIS) Cyclically Adjusted Book per Share: €16.65 (As of Mar. 2026)


FRA:GIS Gilead Sciences Inc FRA:GIS
69 GF Score
Price €114.88
GF Value €84.05
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted Book per Share?

Gilead Sciences FRA:GIS +0.44% 69 Cyclically Adjusted Book per Share is €16.65 as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €84.05 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share for the three months ended in Mar. 2026 was €16.377. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €16.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Book Growth Rate was 4.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 8.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Gilead Sciences was 29.80% per year. The lowest was 2.40% per year. And the median was 23.40% per year.

As of today (2026-07-06), Gilead Sciences's current stock price is €114.88. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €16.65. Gilead Sciences's Cyclically Adjusted PB Ratio of today is 6.90.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 15.13. The lowest was 3.56. And the median was 5.95.


Gilead Sciences  (FRA:GIS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=114.88/16.65
=6.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 15.13. The lowest was 3.56. And the median was 5.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Gilead Sciences Cyclically Adjusted Book per Share Related Terms


Gilead Sciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted Book per Share Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.88 15.06 15.93 17.86 16.27

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.17 15.86 16.38 16.27 16.65

FRA:GIS vs PFE, AMGN, BMY: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.


FRA:GIS
69GF Score
Gilead Sciences Inc FRA:GIS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.377/330.2130*330.2130
=16.377

Current CPI (Mar. 2026) = 330.2130.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 10.388 241.018 14.232
201609 11.369 241.428 15.550
201612 13.668 241.432 18.694
201703 14.623 243.801 19.806
201706 15.454 244.955 20.833
201709 15.949 246.819 21.338
201712 13.206 246.524 17.689
201803 12.846 249.554 16.998
201806 14.314 251.989 18.757
201809 15.141 252.439 19.806
201812 14.664 251.233 19.274
201903 15.249 254.202 19.809
201906 15.804 256.143 20.374
201909 14.778 256.759 19.006
201912 16.013 256.974 20.577
202003 15.926 258.115 20.375
202006 12.766 257.797 16.352
202009 11.820 260.280 14.996
202012 11.931 260.474 15.125
202103 12.695 264.877 15.826
202106 13.041 271.696 15.850
202109 14.541 274.310 17.504
202112 14.869 278.802 17.611
202203 14.417 287.504 16.559
202206 15.266 296.311 17.013
202209 16.979 296.808 18.890
202212 16.079 296.797 17.889
202303 15.714 301.836 17.191
202306 15.660 305.109 16.948
202309 16.766 307.789 17.987
202312 16.803 306.746 18.088
202403 12.940 312.332 13.681
202406 13.632 314.175 14.328
202409 13.359 315.301 13.991
202412 14.812 315.605 15.498
202503 14.237 319.799 14.701
202506 13.734 322.561 14.060
202509 14.776 324.800 15.022
202512 15.627 324.054 15.924
202603 16.377 330.213 16.377

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €16.65 mean?
Gilead Sciences (FRA:GIS) has a Cyclically Adjusted Book per Share of €16.65 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Cyclically Adjusted Book per Share too high?
Gilead Sciences' current Cyclically Adjusted Book per Share is €16.65. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cyclically Adjusted Book per Share compare to PFE and AMGN?
Gilead Sciences' Cyclically Adjusted Book per Share of €16.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Cyclically Adjusted Book per Share is €16.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €84.05, compared to a current price of €114.88 — trading 36.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is €16.65. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Cyclically Adjusted Book per Share is €16.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €114.88 is trading 36.7% above its estimated GF Value™ of €84.05. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Cyclically Adjusted Book per Share: €16.65
  • GF Value™: €84.05 vs. price of €114.88 (36.7% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for FRA:GIS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€114.88
Price
€84.05
GF Value